Tedisamil

DB06200ExperimentalSmall molecule

Tedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter. It is currently being developed by Solvay and is currently under regulatory review by the...

Mechanism: It is hypothesized tedisamil prevents Ca2+ overload by the cAMP dependent SR Ca2+ uptake [PMID: 10707827].
Curator reviewed
Primary indication: Investigated for use/treatment in arrhythmia, atrial fibrillation, and angina.Curator reviewed
Formula / weight: C₁₉H₃₂N₂ · 288.4708 g/mol (avg)
Code names: KC-8857

Resolves to

Compound

UNIIA5VAY2U3R8CAS90961-53-8ChEMBLCHEMBL113461PubChem65825

Clinical / RWD

ATCC01BD06

Structure

InChIKeyCTIRHWCPXYGDGF-UHFFFAOYSA-NSMILESC(C1CC1)N1CC2CN(CC3CC3)CC(C1)C21CCCC1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

457Drug interactionsStructured to mechanism, not free text

1ATC codeIncluding every combination product, plus 10 drug categories

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Tedisamil, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account